Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp228 | Thyroid Cancer - Diagnostics & Treatments | ECE2018

Familial non-medullary thyroid carcinoma. Are we facing a different entity?

Remon-Ruiz Pablo , Romero-Lluch Ana , Duenas-Disotuar Suset , Cuenca Ignacio , Martos-Martinez Juan , Navarro Elena

Background: Familial non medullary thyroid carcinoma (FNMTC) is a not very well known histopatologic entity. Nowadays there are controversial publications about his aggresiveness and prognosisObjective: To know the clinical outcomes and histopathological characteristics of our patients with FNMTC and to compare them with a cohort of patients with sporadic non medullary thyroid carcinoma (CDT).Methods: We conducted a retrospective d...

ea0081p218 | Thyroid | ECE2022

Results of radioiodine remnant ablation with 30 mci dose in low-risk differentiated thyroid carcinoma (dtc)

De Lara-Rodriguez Irene , Duenas Disotuar Suset , Romero Lluch Ana R. , Luis Tirado-Hospital Juan , Pinar Gutierrez Ana , Navarro Elena

Background: The indication of ablation with I131 in low-risk DTC is controversial. The exact dose needed for thyroid remnant ablation is still a matter of debate in low-risk DTC patients. However, low dose has been found to be equally effective as high dose in terms of recurrence rate in recent studies. Taking this into account the current trend is to administer lower doses, although some studies describe a higher rate of retreatment.Aims: 1. To examine ...

ea0090ep580 | Endocrine-related Cancer | ECE2023

Real world efficacy and safety of multikinase inhibitors in patients with advance differentiated thyroid cancer

Duenas-Disotuar Suset , Manuel Canelo-Moreno Juan , De Lara-Rodriguez Irene , Romero-Lluch Ana , Navarro-Gonzalez Elena

Purpose: To establish the safety and efficacy of multikinase inhibitors (MKIs) treatment in real life.Methods: This retrospective observational descriptive study included patients with advanced differentiated thyroid cancer in treatment with MKIs as first and second line treatment. From November 2011 to May 2022. Clinical variables, efficacy and adverse events (AE) were collected. Variables are expressed as median and interquartile range.<p class="ab...

ea0090ep966 | Thyroid | ECE2023

Bone metastases of differentiated thyroid cancer: characteristics and prognostic factors in a multicenter series

Pinar Gutierrez Ana , R. Romero-Lluch Ana , Duenas Disotuar Suset , De Lara-Rodriguez Irene , Angeles Galvez Moreno Maria , Martin Hernandez Tomas , Garcia Aleman Jorge , Martinez-de Pinillos Guillermo , Sanchez-Malo Carolina , Navarro Elena

Objective: To describe the characteristics, survival and prognostic factors of a cohort of patients with bone metastases (BM) of differentiated thyroid carcinoma (DTC).Methods: Multicenter retrospective observational study. Patients diagnosed with DTC and BM between 1980-2021 were included. A Cox regression was performed to study prognostic factors for 5- and 10-year survival. Kaplan-Meier and log-rank tests were performed for survival analysis and compa...